

Press release

Hørsholm  
28 August 2014

## **ALK to participate at the Goldman Sachs European Biotech Symposium in London**

Page 1/1

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will be hosting investor meetings during the Goldman Sachs European Biotech Symposium to be held in London on Friday, 5 September 2014. Per Plotnikof, Director IR and Strategic Planning, will give an overview of the Company and its key programmes.

### **ALK-Abelló A/S**

#### **For further information please contact:**

*Investor Relations:* Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Janet Dally, tel. +1 609-466-0466

*Press:* Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

#### **About ALK**

*ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy – a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck (MSD outside the USA and Canada) and Torii to commercialise allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at [www.alk.net](http://www.alk.net).*